| 标题： | 乳腺癌风险评估与高危人群筛选临床实践指南2021.V1（CSBrS-Guideline-01） |
| title： | Clinical Practice Guidelines for Risk Assessment to Identify Women at High Risk of Breast Cancer: Chinese Society of Breast Surgery (CSBrS) Practice Guidelines 2021 |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 标准指南 |
| classification： | Standard guideline |
| 领域： | 预防 |
| field： | Prevention |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 中国乳腺疾病专业临床医生 |
| Guide users： | Chinese clinicians specialized in breast diseases |
| 证据分级方法： | The level of evidence grading system was developed by referring to the GRADE system combined with findings in clinical studies in China. The levels are classified as Category I, II, III, and IV to quantify the evaluation of the reliability of the evidence by experts on the compiling committees. To make these guidelines accessible in clinical practice in China, the expert panel preferentially selected Category I and II evidence, as indicated in the guideline evaluation system. I Based on high-level prospective randomized controlled clinical trials, observational studies or meta-analyses with large sample sizes, internationally-recognized current guidelines and consensus statements, published guidelines and consensus statements from national societies or associations, Chinese population-based studies of the above types published in SCI journals, MEDLINE journals, and Chinese series journals II Based on low-level randomized clinical trials, well-designed non-controlled trials or cohort studies, inter-continental professional association guidelines and international conference expert consensus statements, published guidelines and consensus statements from national regional societies or associations, Chinese population-based studies of the above types published in PKU core journals III Based on case-control studies or retrospective studies, published guidelines and consensus statements from national professional associations, and provincial societies or associations, Chinese population-based studies of the above types published in source journals for Chinese scientific and technical papers and citations IV Based on case reports, scientific hypotheses, regional expert consensus statements and published guidelines and consensus statements from national local societies or associations, Chinese population-based studies of the above types published in non-aforementioned core journals |
| Evidence grading method： | |
| 制定单位： | 中华医学会外科学分会乳腺外科学组 |
| Formulating unit： | Chinese Society of Breast Surgery |
| 注册时间： | 2021-06-01 |
| Registration time： | |
| 注册编号： | IPGRP-2021CN133 |
| Registration number： | |
| 指南制订的目的： | 乳腺癌是中国女性最常见的恶性肿瘤，发病率呈现持续快速上升趋势。2015年中国新发乳腺癌病例30.4万，占所有女性新发恶性肿瘤的17.1%，位居女性恶性肿瘤发病首位，防控形势严峻[1,2]。目前，中国乳腺癌预防仍以乳腺B超及乳腺X线等影像学筛查为主，缺乏有效的一级预防措施。美国预防医学工作组（US Preventive Services Task Force，USPSTF）[3]及美国国立综合癌症网络（National Comprehensive Cancer Network，NCCN）乳腺癌临床实践指南[4]推荐通过风险评估筛选乳腺癌高危人群，并在此基础上开展乳腺癌筛查和/或药物干预，以降低女性乳腺癌罹患风险。 |
| Purpose of the guideline： | Breast cancer is the most common malignancy among women in China, and there has been an obvisous ever-increasing trend of incidence over the past decades, resulting in a great social and economic burden. Approximately 304 thousands of new breast cancer cases were diagnosed in 2015 in China, ranking the first leading cancer diagnosis and accounting for 17.1% of all new cancers in women. [1,2] Currently, image-based screening program, using ultrasound and/or mammography, has been proposed as one of the most important strategies and become the most common efforts to lower breast cancer burden in China, though primary prevention measures are still lacking. Both US Preventive Services Task Force (USPSTF)[3] and National Comprehensive Cancer Network (NCCN) clinical practice guidelines[4] have made recommendations on risk assessment to identify women at increased risk for breast cancer, for whom risk-based cancer screening and/or risk-reducing medication use should be provided in order to lower the individual breast cancer risk. |
